parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.11 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in schwann cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	108 Parkinson's papers of 4,472	0.38
pathways Reactome	4 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 2448

receipt 2456: S100B in dopamine neurons, braak

power: full sample +0.17 (p 0.498, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.735, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.188, n 18). could be the mix.
skeptic: leave-one-out range +0.07 to +0.31, sign flips 0; without severely affected donors +0.17 (p 0.498, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for S100B in dopamine neurons.

case closed: nothing better to follow up.

receipt 2455: S100B in oligodendrocytes, braak

power: full sample +0.25 (p 0.319, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.603, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.17 (p 0.509, n 18). could be the mix.
skeptic: leave-one-out range +0.16 to +0.40, sign flips 0; without severely affected donors +0.25 (p 0.319, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for S100B in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts